Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors

Mohamed Shanavas, Uday Popat, Laura C. Michaelis, Veena Fauble, Donal McLornan, Rebecca Klisovic, John Mascarenhas, Roni Tamari, Murat O. Arcasoy, James Davies, Usama Gergis, Oluchi C. Ukaegbu, Rammurti T. Kamble, John M. Storring, Navneet S. Majhail, Rizwan Romee, Srdan Verstovsek, Antonio Pagliuca, Sumithira Vasu, Brenda ErnstEshetu G. Atenafu, Ahmad Hanif, Richard Champlin, Paremeswaran Hari, Vikas Gupta

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The impact of Janus kinase (JAK) 1/2 inhibitor therapy before allogeneic hematopoietic cell transplantation (HCT) has not been studied in a large cohort in myelofibrosis (MF). In this retrospective multicenter study, we analyzed outcomes of patients who underwent HCT for MF with prior exposure to JAK1/2 inhibitors. One hundred consecutive patients from participating centers were analyzed, and based on clinical status and response to JAK1/2 inhibitors at the time of HCT, patients were stratified into 5 groups: (1) clinical improvement (n = 23), (2) stable disease (n = 31), (3) new cytopenia/increasing blasts/intolerance (n = 15), (4) progressive disease: splenomegaly (n = 18), and (5) progressive disease: leukemic transformation (LT) (n = 13). Overall survival (OS) at 2 years was 61% (95% confidence interval [CI], 49% to 71%). OS was 91% (95% CI, 69% to 98%) for those who experienced clinical improvement and 32% (95% CI, 8% to 59%) for those who developed LT on JAK1/2 inhibitors. In multivariable analysis, response to JAK1/2 inhibitors (P = .03), dynamic international prognostic scoring system score (P = .003), and donor type (P = .006) were independent predictors of survival. Among the 66 patients who remained on JAK1/2 inhibitors until stopped for HCT, 2 patients developed serious adverse events necessitating delay of HCT and another 8 patients had symptoms with lesser severity. Adverse events were more common in patients who started tapering or abruptly stopped their regular dose ≥6 days before conditioning therapy. We conclude that prior exposure to JAK1/2 inhibitors did not adversely affect post-transplantation outcomes. Our data suggest that JAK1/2 inhibitors should be continued near to the start of conditioning therapy. The favorable outcomes of patients who experienced clinical improvement with JAK1/2 inhibitor therapy before HCT were particularly encouraging, and need further prospective validation.

Original languageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
DOIs
StateAccepted/In press - Sep 10 2015

Fingerprint

Janus Kinase 1
Janus Kinase 2
Primary Myelofibrosis
Cell Transplantation
Behavior Therapy
Confidence Intervals
Survival
Splenomegaly
Multicenter Studies
Retrospective Studies
Transplantation
Tissue Donors

Keywords

  • Allogeneic transplantation
  • JAK1/2 inhibitors
  • Myelofibrosis
  • Ruxolitinib
  • Survival

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. / Shanavas, Mohamed; Popat, Uday; Michaelis, Laura C.; Fauble, Veena; McLornan, Donal; Klisovic, Rebecca; Mascarenhas, John; Tamari, Roni; Arcasoy, Murat O.; Davies, James; Gergis, Usama; Ukaegbu, Oluchi C.; Kamble, Rammurti T.; Storring, John M.; Majhail, Navneet S.; Romee, Rizwan; Verstovsek, Srdan; Pagliuca, Antonio; Vasu, Sumithira; Ernst, Brenda; Atenafu, Eshetu G.; Hanif, Ahmad; Champlin, Richard; Hari, Paremeswaran; Gupta, Vikas.

In: Biology of Blood and Marrow Transplantation, 10.09.2015.

Research output: Contribution to journalArticle

Shanavas, M, Popat, U, Michaelis, LC, Fauble, V, McLornan, D, Klisovic, R, Mascarenhas, J, Tamari, R, Arcasoy, MO, Davies, J, Gergis, U, Ukaegbu, OC, Kamble, RT, Storring, JM, Majhail, NS, Romee, R, Verstovsek, S, Pagliuca, A, Vasu, S, Ernst, B, Atenafu, EG, Hanif, A, Champlin, R, Hari, P & Gupta, V 2015, 'Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2015.10.005
Shanavas, Mohamed ; Popat, Uday ; Michaelis, Laura C. ; Fauble, Veena ; McLornan, Donal ; Klisovic, Rebecca ; Mascarenhas, John ; Tamari, Roni ; Arcasoy, Murat O. ; Davies, James ; Gergis, Usama ; Ukaegbu, Oluchi C. ; Kamble, Rammurti T. ; Storring, John M. ; Majhail, Navneet S. ; Romee, Rizwan ; Verstovsek, Srdan ; Pagliuca, Antonio ; Vasu, Sumithira ; Ernst, Brenda ; Atenafu, Eshetu G. ; Hanif, Ahmad ; Champlin, Richard ; Hari, Paremeswaran ; Gupta, Vikas. / Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. In: Biology of Blood and Marrow Transplantation. 2015.
@article{931ec0c48488427ea4c3ef093570e428,
title = "Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors",
abstract = "The impact of Janus kinase (JAK) 1/2 inhibitor therapy before allogeneic hematopoietic cell transplantation (HCT) has not been studied in a large cohort in myelofibrosis (MF). In this retrospective multicenter study, we analyzed outcomes of patients who underwent HCT for MF with prior exposure to JAK1/2 inhibitors. One hundred consecutive patients from participating centers were analyzed, and based on clinical status and response to JAK1/2 inhibitors at the time of HCT, patients were stratified into 5 groups: (1) clinical improvement (n = 23), (2) stable disease (n = 31), (3) new cytopenia/increasing blasts/intolerance (n = 15), (4) progressive disease: splenomegaly (n = 18), and (5) progressive disease: leukemic transformation (LT) (n = 13). Overall survival (OS) at 2 years was 61{\%} (95{\%} confidence interval [CI], 49{\%} to 71{\%}). OS was 91{\%} (95{\%} CI, 69{\%} to 98{\%}) for those who experienced clinical improvement and 32{\%} (95{\%} CI, 8{\%} to 59{\%}) for those who developed LT on JAK1/2 inhibitors. In multivariable analysis, response to JAK1/2 inhibitors (P = .03), dynamic international prognostic scoring system score (P = .003), and donor type (P = .006) were independent predictors of survival. Among the 66 patients who remained on JAK1/2 inhibitors until stopped for HCT, 2 patients developed serious adverse events necessitating delay of HCT and another 8 patients had symptoms with lesser severity. Adverse events were more common in patients who started tapering or abruptly stopped their regular dose ≥6 days before conditioning therapy. We conclude that prior exposure to JAK1/2 inhibitors did not adversely affect post-transplantation outcomes. Our data suggest that JAK1/2 inhibitors should be continued near to the start of conditioning therapy. The favorable outcomes of patients who experienced clinical improvement with JAK1/2 inhibitor therapy before HCT were particularly encouraging, and need further prospective validation.",
keywords = "Allogeneic transplantation, JAK1/2 inhibitors, Myelofibrosis, Ruxolitinib, Survival",
author = "Mohamed Shanavas and Uday Popat and Michaelis, {Laura C.} and Veena Fauble and Donal McLornan and Rebecca Klisovic and John Mascarenhas and Roni Tamari and Arcasoy, {Murat O.} and James Davies and Usama Gergis and Ukaegbu, {Oluchi C.} and Kamble, {Rammurti T.} and Storring, {John M.} and Majhail, {Navneet S.} and Rizwan Romee and Srdan Verstovsek and Antonio Pagliuca and Sumithira Vasu and Brenda Ernst and Atenafu, {Eshetu G.} and Ahmad Hanif and Richard Champlin and Paremeswaran Hari and Vikas Gupta",
year = "2015",
month = "9",
day = "10",
doi = "10.1016/j.bbmt.2015.10.005",
language = "English (US)",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors

AU - Shanavas, Mohamed

AU - Popat, Uday

AU - Michaelis, Laura C.

AU - Fauble, Veena

AU - McLornan, Donal

AU - Klisovic, Rebecca

AU - Mascarenhas, John

AU - Tamari, Roni

AU - Arcasoy, Murat O.

AU - Davies, James

AU - Gergis, Usama

AU - Ukaegbu, Oluchi C.

AU - Kamble, Rammurti T.

AU - Storring, John M.

AU - Majhail, Navneet S.

AU - Romee, Rizwan

AU - Verstovsek, Srdan

AU - Pagliuca, Antonio

AU - Vasu, Sumithira

AU - Ernst, Brenda

AU - Atenafu, Eshetu G.

AU - Hanif, Ahmad

AU - Champlin, Richard

AU - Hari, Paremeswaran

AU - Gupta, Vikas

PY - 2015/9/10

Y1 - 2015/9/10

N2 - The impact of Janus kinase (JAK) 1/2 inhibitor therapy before allogeneic hematopoietic cell transplantation (HCT) has not been studied in a large cohort in myelofibrosis (MF). In this retrospective multicenter study, we analyzed outcomes of patients who underwent HCT for MF with prior exposure to JAK1/2 inhibitors. One hundred consecutive patients from participating centers were analyzed, and based on clinical status and response to JAK1/2 inhibitors at the time of HCT, patients were stratified into 5 groups: (1) clinical improvement (n = 23), (2) stable disease (n = 31), (3) new cytopenia/increasing blasts/intolerance (n = 15), (4) progressive disease: splenomegaly (n = 18), and (5) progressive disease: leukemic transformation (LT) (n = 13). Overall survival (OS) at 2 years was 61% (95% confidence interval [CI], 49% to 71%). OS was 91% (95% CI, 69% to 98%) for those who experienced clinical improvement and 32% (95% CI, 8% to 59%) for those who developed LT on JAK1/2 inhibitors. In multivariable analysis, response to JAK1/2 inhibitors (P = .03), dynamic international prognostic scoring system score (P = .003), and donor type (P = .006) were independent predictors of survival. Among the 66 patients who remained on JAK1/2 inhibitors until stopped for HCT, 2 patients developed serious adverse events necessitating delay of HCT and another 8 patients had symptoms with lesser severity. Adverse events were more common in patients who started tapering or abruptly stopped their regular dose ≥6 days before conditioning therapy. We conclude that prior exposure to JAK1/2 inhibitors did not adversely affect post-transplantation outcomes. Our data suggest that JAK1/2 inhibitors should be continued near to the start of conditioning therapy. The favorable outcomes of patients who experienced clinical improvement with JAK1/2 inhibitor therapy before HCT were particularly encouraging, and need further prospective validation.

AB - The impact of Janus kinase (JAK) 1/2 inhibitor therapy before allogeneic hematopoietic cell transplantation (HCT) has not been studied in a large cohort in myelofibrosis (MF). In this retrospective multicenter study, we analyzed outcomes of patients who underwent HCT for MF with prior exposure to JAK1/2 inhibitors. One hundred consecutive patients from participating centers were analyzed, and based on clinical status and response to JAK1/2 inhibitors at the time of HCT, patients were stratified into 5 groups: (1) clinical improvement (n = 23), (2) stable disease (n = 31), (3) new cytopenia/increasing blasts/intolerance (n = 15), (4) progressive disease: splenomegaly (n = 18), and (5) progressive disease: leukemic transformation (LT) (n = 13). Overall survival (OS) at 2 years was 61% (95% confidence interval [CI], 49% to 71%). OS was 91% (95% CI, 69% to 98%) for those who experienced clinical improvement and 32% (95% CI, 8% to 59%) for those who developed LT on JAK1/2 inhibitors. In multivariable analysis, response to JAK1/2 inhibitors (P = .03), dynamic international prognostic scoring system score (P = .003), and donor type (P = .006) were independent predictors of survival. Among the 66 patients who remained on JAK1/2 inhibitors until stopped for HCT, 2 patients developed serious adverse events necessitating delay of HCT and another 8 patients had symptoms with lesser severity. Adverse events were more common in patients who started tapering or abruptly stopped their regular dose ≥6 days before conditioning therapy. We conclude that prior exposure to JAK1/2 inhibitors did not adversely affect post-transplantation outcomes. Our data suggest that JAK1/2 inhibitors should be continued near to the start of conditioning therapy. The favorable outcomes of patients who experienced clinical improvement with JAK1/2 inhibitor therapy before HCT were particularly encouraging, and need further prospective validation.

KW - Allogeneic transplantation

KW - JAK1/2 inhibitors

KW - Myelofibrosis

KW - Ruxolitinib

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84950996639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950996639&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2015.10.005

DO - 10.1016/j.bbmt.2015.10.005

M3 - Article

C2 - 26493563

AN - SCOPUS:84950996639

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -